Conversion therapy of Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6 in patients with liver metastatic colorectal cancer
- Conditions
- nresectable colorectal liver metastases
- Registration Number
- JPRN-UMIN000004694
- Lead Sponsor
- agoya Surgical Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
(1)Severe myelosuppression (2)Diarrhea(watery) (3)Require treatment of serious infection (4)Uncontrolled body cavity fluid (5)Comorbidity or history of interstitial lung disease or pulmonary fibrosis (6)Severe hypersensitivity (7)Renal failure or urine protein >=+2 within 1 week before enrollment (8)Uncontrollable hypertension or diabetes (9)Significant abnormal ECG or history of cardiovascular disease within 1year (10)Thrombosis with present or history of thromboembolism within 1year (11)Intestinal bleeding, ileus, bowel obstruction or peptic ulcer (12)Perforation of gastrointestinal tract within 1year (13)Administrated with Aspirin (>=325mg/day) or steroid for rheumatoid arthritis and chronic inflammatory disease (14)Pregnant and lacting woman,woman with suspected pregnancy, and men of the fertility hope (15)Have anti-thrombosis drugs within 7days before enrollment (16)Need to treatment with Atazanavir sulfate (17)Active multiple cancers (18)Severe mental illness (19)Treated continuously with systemic steroids (20)Any subject judged by the investigator to be unfit for any reason to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method